Our team is passionate about global situations and strongly supports just patent regulations that ensure vital medications are affordable to those in all regions and countries. Although the intent of the TRIPS agreement was to positively aid people world over, the provisions of the agreement are actually having detrimental effects on the impoverished developing countries. For the sake of public health, we ardently believe that the TRIPS agreement must be re-evaluated and modified, taking into account the viability and longevity of any solutions agreed upon. At hand we have an acute AIDS crisis that is viciously decimating the international population without regard for background, nationality, religion, or economic standing. The lone way to impede and combat the epidemic, we believe, is for a global coalition to intervene and actively engage the situation. The incessant litigious assaults spewed forth by dominant western pharmaceuticals must cease. This is not the panacea; what we desperately need is an easily understood and readily accepted collective solution.

In addition, while supporting Intellectual Property (IP) regulations, we firmly believe that these regulations should be flexible so as to adequately provide for those countries in need. And while allowing and providing for flexibility, the community can not only honor and ensure IP security, but also additionally ensure that an all encompassing, generalizing policy does not unduly harm developing and poorer countries.

Thus, we suggest that the United States Trade Representative (USTR) partake in the multilateral TRIPS Council negotiations in regards to the topic of HIV/AIDS drug patents, and advocate a feasible and internationally tolerable solution that makes life-saving medicine accessible to countries currently lacking in manufacturing capability.